Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
作者： A Atmaca , S-E Al-Batran , A Maurer , A Neumann , T Heinzel
关键词:
摘要: … Twenty-six pre-treated patients with progressing solid tumours were enrolled in dose-escalating three-patient cohorts, starting at a dose of VPA 30 mg kg −1 day −1 . VPA was …
nature.com
sci-hub.se 参考文章(23)
Ulrich Mahlknecht, Dieter Hoelzer, Histone acetylation modifiers in the pathogenesis of malignant disease. Molecular Medicine. ,vol. 6, pp. 623- 644 ,(2000) , 10.1007/BF03402044
Gesine Bug, Markus Ritter, Barbara Wassmann, Claudia Schoch, Thorsten Heinzel, Kerstin Schwarz, Annette Romanski, Oliver H. Kramer, Manuela Kampfmann, Dieter Hoelzer, Andreas Neubauer, Martin Ruthardt, Oliver G. Ottmann, Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer. ,vol. 104, pp. 2717- 2725 ,(2005) , 10.1002/CNCR.21589
Louise B. Grochow, Mario A. Eisenberger, Victoria Sinibaldi, Yelena Zabelina, M. Katherine Bowling, Dennis Noe, Jill Gilbert, Michael A. Carducci, Ross C. Donehower, Tian-ling Chen, A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule Clinical Cancer Research. ,vol. 7, pp. 3047- 3055 ,(2001)
Victoria M. Richon, Marija Drobnjak, Owen O’Connor, Judy H. Chiao, Stacie Richardson, Tracy Curley, Carlos Cordon-Cordo, Barbara MacGregor-Curtelli, William Tong, Eddie Rosa, Paul A. Marks, Richard Rifkind, Lawrence Schwartz, Howard Scher, Mark Klang, Wm. Kevin Kelly, Wm. Kevin Kelly, Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously Clinical Cancer Research. ,vol. 9, pp. 3578- 3588 ,(2003)
Hui Yang, Koyu Hoshino, Blanca Sanchez-Gonzalez, Hagop Kantarjian, Guillermo Garcia-Manero, Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid Leukemia Research. ,vol. 29, pp. 739- 748 ,(2005) , 10.1016/J.LEUKRES.2004.11.022
Tony Kouzarides, Histone acetylases and deacetylases in cell proliferation. Current Opinion in Genetics & Development. ,vol. 9, pp. 40- 48 ,(1999) , 10.1016/S0959-437X(99)80006-9
Brian D. Strahl, C. David Allis, The language of covalent histone modifications. Nature. ,vol. 403, pp. 41- 45 ,(2000) , 10.1038/47412
Andrea Kuendgen, Mathias Schmid, Richard Schlenk, Sabine Knipp, Barbara Hildebrandt, Christian Steidl, Ulrich Germing, Rainer Haas, Hartmut Dohner, Norbert Gattermann, The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer. ,vol. 106, pp. 112- 119 ,(2006) , 10.1002/CNCR.21552
Wolfgang Löscher, Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action Progress in Neurobiology. ,vol. 58, pp. 31- 59 ,(1999) , 10.1016/S0301-0082(98)00075-6
James R Davie, Covalent modifications of histones: expression from chromatin templates Current Opinion in Genetics & Development. ,vol. 8, pp. 173- 178 ,(1998) , 10.1016/S0959-437X(98)80138-X